STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALGS
  4. [Form 4] Aligos Therapeutics, Inc. Insider Trading Activity

Aligos Therapeutics (ALGS) director receives stock options for 5,860 shares at $5.50

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aligos Therapeutics director Peter Hirth received a stock option grant for 5,860 shares of common stock at an exercise price of $5.50 per share. The option vests in full on the earlier of the first anniversary of the grant date or immediately before the 2027 annual stockholder meeting, assuming continuous service, and expires in 2036.

Positive

  • None.

Negative

  • None.
Insider Hirth Peter
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 5,860 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 5,860 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 5,860 options Stock option award to director Peter Hirth
Exercise price $5.50 per share Strike price for granted stock options
Expiration date June 25, 2036 Option term end date
Post-grant derivative holdings 5,860 options Total options held after transaction
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 5.5000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
vest and become exercisable financial
"The shares subject to the option will vest and become exercisable as to 100%..."
continuous service financial
"subject to continuous service to the Issuer through such vesting date"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hirth Peter
(Last)(First)(Middle)
C/O ALIGOS THERAPEUTICS, INC.
1 CORPORATE DRIVE, 2ND FLOOR
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$5.506/25/2026A5,860 (1)06/25/2036Common Stock5,860$05,860D
Explanation of Responses:
1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.
/s/ Lesley Ann Calhoun, as attorney-in fact for Peter Hirth06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Aligos Therapeutics (ALGS) report for Peter Hirth?

Aligos Therapeutics reported that director Peter Hirth received a stock option grant for 5,860 shares of common stock at a $5.50 exercise price. This is a compensation-related award, not an open-market purchase or sale of existing shares.

What are the terms of Peter Hirth’s new Aligos Therapeutics (ALGS) stock options?

The new stock options give Peter Hirth the right to buy 5,860 Aligos common shares at $5.50 per share. They vest 100% on the earlier of the first anniversary of the grant or immediately before the 2027 annual meeting, subject to continuous service.

When do Peter Hirth’s Aligos Therapeutics (ALGS) options expire?

Peter Hirth’s stock options are scheduled to expire on June 25, 2036. He must exercise them before that date, once vested, to acquire up to 5,860 Aligos common shares at the fixed $5.50 exercise price per share.

Is Peter Hirth’s Form 4 transaction in Aligos Therapeutics (ALGS) a buy or a sale?

The Form 4 shows an acquisition of derivative securities through a stock option grant, not an open-market buy or sale. The code “A” indicates a grant or award, reflecting compensation rather than a discretionary trading decision in Aligos shares.

How many Aligos Therapeutics (ALGS) options does Peter Hirth hold after this grant?

After this grant, Peter Hirth holds 5,860 stock options according to the filing. These options each relate to one underlying Aligos common share, giving him rights to potentially acquire that number of shares if he exercises the options after vesting.